the moment

I've just read this post in relation to another "specie" my SMSF is invested in (ESI). We hold ESI for the same reason we hold NSP.... because of the potential of its IP.
Couldn't help but think (perhaps a little bit too optomistically) that there are real parallels with the progress of NSP which I have been following for a similar period:

"Great post Megagene.

Too right re all of your post but especially this bit:
"Firstly one must look at lind's past and 3 of the team Jeffrey Easton, Phillip Valliere and Arlene Brownstein were part of Springtree which were part of the funding arrangement with PRR that saw it go from a dead spec in the 1c range to a 300 mill market cap company. And the common denominator as the other part of the Lind team is former PRR Managing Director Martin Rogers. Lind backing ESI will definitely open ESI to new investors with deep pockets and promotion of the company through their channels both here and in the US to the potential of ESI"

Martin Rogers, a firm who was involved in PRR's huge re-rating and also the largest oppies holder of ESIO also was in on PRR and made a mint (millions of dollars) holding their options from mega lows to the highs. Ive mentioned it before but Mr Proksa was in a book about it.

Onwards and upwards I agree with you Megagene

All the people who have said in the past that this is a dog of a stock, and said it is going to go under (and their are many of them if you go back reading through the threads) are going to end up with egg on their face IMO.

The Coldry technology has the ability to transform this currently tiny company into a company maker over time (depending on a myriad of factors obviously). GLTAH."

What are the parallels? Over the last 12 months we appear to have been making real progress with acquisition of plant and clinical trials as well as real progress on the regulatory front. But the background since I have been following the stock has, until recently, been a retreating SP. Now there is evidence that we may be approaching our own "Moment" or tipping point when the positives justify a dramatic re-rating of the company's prospects. At least I can share this sentiment happy New Year and good luck to all in 2014, when I'm hopeful "the Moment" will finally dawn!

Kind regards,